Skip to content Skip to footer
Subscribe Now
Viewpoints_Dr. Philip Mease
VIEWPOINTS

PharmaShots Interview: Dr. Philip Mease Shares Insights on the Clinical data of Tremfya (guselkumab) Presented in The Lancet Rheumatology

In an interview with PharmaShots, Dr. Philip Mease, MD, Seattle Rheumatology Associates shares insights on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in The Lancet Rheumatology Shots: The P-III trials consist of two studies i.e., DISCOVER-1 & 2 evaluates Tremfya in 1100 patients with PsA who have axial symptoms The results demonstrated efficacy…
September 22, 2021

Read more

Viewpoints_James E. Brown
VIEWPOINTS

PharmaShots Interview: Durect’s James E. Brown Shares Insight on the Data of DUR-928 Presented at EASL 2021

In an interview with PharmaShots, James E. Brown, President, CEO, and Director of Durect shared his views on the clinical data of DUR-928 in P-1b trial for NASH and P-I trial for Hepatic Impairment Shots: The P-Ib trial evaluates DUR-928 (50/150/600mg for 4wks.) in 65 patients with NASH with stage 1-3 fibrosis which showed improvement…
September 20, 2021

Read more

Exclusive_Ron Elwell_2021
EXCLUSIVE

Exclusive Interview with PharmaShots: Ron Elwell of IPM.ai Shares Insight on the Simplification of Patient Recruitment by Applying AI and ML to Real-World Data

In an interview with PharmaShots, Ron Elwell, President, and Founder of Swoop and IPM.ai shared his views on the Real Chemistry Clinical Trial Recruitment System that is designed to accelerate clinical investigations and lead to faster patient outcomes with less risk. Shots: Real Chemistry’s IPM.ai accelerates clinical investigation & commercialization of precision medicines leveraging AI and ML…
September 20, 2021

Read more

Viewpoints_Dr. Dale Christensen
VIEWPOINTS

PharmaShots Interview: TFF’s Dr. Dale Christensen Shares Insight on the Thin Film Freezing Technology

In an interview with PharmaShots, Dr. Dale Christensen, Ph.D., Director of Clinical Development at TFF Pharmaceuticals shared his views on the preliminary data from the P-I trial of inhalable tacrolimus powder formulation for Lung Transplant & its TFF technology Shots: TFF has developed an inhalable tacrolimus powder formulation that can be delivered directly to the lung via an inhaler bypassing…
September 15, 2021

Read more

Viewpoints_James Graham
VIEWPOINTS

PharmaShots Interview: Recce Pharmaceuticals’ James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Infected Burn Wounds

In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds. Shots: The multiple patients have been dosed in P-I/II trial evaluates the effectiveness & safety of RECCE 327 in 30 patients (10 will receive RECCE 327…
September 14, 2021

Read more

Viewpoints_Dr. Ian Walters
VIEWPOINTS

PharmaShots Interview: Portage Biotech’s Dr. Ian Walters Shares Insight on the Data of INT230-6 Presented at ASCO 2021

In an interview with PharmaShots, Dr. Ian Walters, CEO of Portage Biotech shared his views on the interim data from the P-II IT-01 trial evaluates the safety and efficacy of INT230-6 as both a monotherapy and in combination with pembrolizumab or ipilimumab in solid tumors Shots: The P-II IT-01 trial evaluates the safety & efficacy of INT230-6 as monothx. & in…
September 13, 2021

Read more

Exclusive_Kelly Pokuta1_April Kunze2_2021
EXCLUSIVE

Exclusive Interview with PharmaShots: Kelly Pokuta and April Kunze of Prime Therapeutics Share Insight on MedDrive, a Medical Drug Management Program

In an exclusive interview with PharmaShots, Kelly Pokuta, Vice President of Pharmaceutical Trade Relations, and April Kunze, Senior Director, Clinical Formulary Development & Trend Management Strategy at Prime therapeutics share their views on the MedDrive as a first-of-its-kind medical drug management program uniquely aligned with its Blue Plan clients. Shots: Prime introduced the first-of-its-kind medical drug management solution with…
September 7, 2021

Read more

Viewpoints_Paula Ragan
VIEWPOINTS

Pharmashots Interview: Paula Ragan Shares Insights on the Data of Mavorixafor in Combination with Ibrutinib Presented at 2021 EHA Annual Congress

In an interview with PharmaShots, Paula Ragan, Ph.D., President, and Chief Executive Officer at X4 Pharmaceuticals shared her views on preliminary efficacy and safety data of Mavorixafor + Ibrutinib in an ongoing P-Ib study to treat waldenström's macroglobulinemia Shots: The ongoing P-Ib clinical trial evaluates the safety & efficacy of mavorixafor + ibrutinib in patients with WM with both MYD88 &…
September 3, 2021

Read more

Load more